Executive Summary
The 11 filings for the BSE PHARMA index on 28 Sep 2026 present a mixed picture of strategic repositioning, regulatory progress, and routine compliance. The most material development is **Mankind Pharma's** decision to voluntarily liquidate its subsidiary Bharat Serums and Vaccines (BSV), a high-risk event that could signal a strategic pivot or asset write-off.
On the positive side, **Sun Pharma** has secured a major licensing deal for a PCSK9 inhibitor (lerodalcibep) targeting a $3.7B ex-US/China market, while **Lupin** has received tentative FDA approval for a novel liquid formulation of Apixaban, strengthening its US pipeline. **Zydus Lifesciences** had a relatively clean USFDA inspection at its Ahmedabad plant, closing with only one observation and no data integrity issues. The sector is entering a quiet period with trading windows closing across multiple companies (Lupin, Glenmark, Cipla, Abbott India, Torrent Pharma) ahead of Q2 FY27 results. Period-over-period trends are not directly comparable across filings, but the forward-looking data points to a sector focused on regulatory compliance, pipeline expansion, and portfolio rationalization. The overall sentiment is cautiously optimistic, tempered by the BSV liquidation risk.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: Insider trading
Tracking the trend? Catch up on the prior BSE Pharma Sector Regulatory Filings digest from September 19, 2026.
Investment Signals (11)
- Sun Pharma ↓ (BULLISH)▲
Secured exclusive licensing deal for lerodalcibep (Lyrokaul), a once-monthly PCSK9 inhibitor, targeting a $3.7B ex-US/China market growing at 38% CAGR. EU approval received Sep 21, 2026. Strengthens Innovative Medicines portfolio significantly
- Lupin ↓ (BULLISH)▲
Received tentative FDA approval for Apixaban Oral Suspension 1.25 mg/mL via 505(b)(2) pathway. Novel liquid formulation of Eliquis® offers alternative for patients with swallowing difficulties. Manufacturing at Somerset, NJ facility upon final approval
- Zydus Lifesciences ↓ (BULLISH)▲
USFDA cGMP inspection at SEZ II, Ahmedabad plant closed with only 1 observation and NO data integrity issues. Outcome is relatively favorable vs. peers, indicating strong compliance culture
- Torrent Pharma ↓ (BULLISH)▲
Increased investment in Torrent Urja 27 (renewable energy SPV) from INR 7.92 Cr to INR 11.88 Cr for 26% stake. Strategic move to secure captive power and comply with electricity regulations, reducing long-term energy cost risk
- Mankind Pharma ↓ (BEARISH)▲
Voluntary liquidation of BSV subsidiary signals potential write-off of past investments. Auditors resigned effective Sep 28, 2026. High materiality event (8/10) with negative sentiment
- Cipla ↓ (NEUTRAL)▲
Board meeting scheduled for Oct 27, 2026 to approve Q2/H1 FY27 results. Trading window closed Oct 1-29. No insider activity data, but standard compliance suggests no material undisclosed events
- Sun Pharma (Postal Ballot) (BULLISH)▲
Shareholders approved resolution by requisite majority via postal ballot (e-voting Aug 28-Sep 26). Indicates strong retail/institutional support for management decisions
- Lupin (Trading Window) (NEUTRAL)▲
Trading window closed Oct 1 until 48h post Q2 results. Standard compliance, no material impact
- Glenmark Pharma ↓ (NEUTRAL)▲
Trading window closed Oct 1 until Q2 results + 48h. Standard compliance
- Abbott India ↓ (NEUTRAL)▲
Trading window closed Oct 1 until 48h post Q3 FY26 results (quarter ending Sep 30, 2026). Standard compliance
- Torrent Pharma (Trading Window) (NEUTRAL)▲
Trading window closed Oct 1 until 48h post Q2 FY27 results. Standard compliance
Risk Flags (7)
- Mankind Pharma/BSV Liquidation↓ [HIGH RISK]▼
Voluntary liquidation of Bharat Serums and Vaccines (BSV) initiated Sep 7, 2026. Auditors resigned effective Sep 28, 2026. High materiality (8/10) with negative sentiment. Potential write-off of past investments and disruption to BSV's operations
- Torrent Pharma/SPV Investment↓ [MEDIUM RISK]▼
Investment in Torrent Urja 27 (renewable SPV) is in a pre-revenue entity (nil turnover as of Mar 31, 2026). Completion timeline of 18-21 months introduces execution risk and capital lock-up
- Zydus Lifesciences/USFDA Observation↓ [MEDIUM RISK]▼
Despite no data integrity issues, 1 observation at SEZ II plant indicates compliance gaps. If not addressed expeditiously, could escalate to warning letter or import alert
- Sun Pharma/Licensing Deal↓ [MEDIUM RISK]▼
Financial terms of lerodalcibep deal are confidential. Drug faces competition from established PCSK9 inhibitors (Repatha, Praluent) and safety considerations. Market penetration may be slower than expected
- Lupin/Apixaban Approval↓ [LOW RISK]▼
Tentative approval only; final approval timing uncertain. Apixaban market faces generic competition and patent litigation risks. Manufacturing at Somerset, NJ facility adds operational complexity
- Mankind Pharma/Auditor Resignation↓ [MEDIUM RISK]▼
Auditors (S.R. Batliboi & Co.) resigned effective Sep 28, 2026, citing liquidation proceedings. While no other material reason given, sudden resignation raises governance questions
- Sector-wide/Trading Window Closures [LOW RISK]▼
5 companies (Lupin, Glenmark, Cipla, Abbott India, Torrent Pharma) closing trading windows from Oct 1. Creates information asymmetry and limits insider trading visibility until Q2 results
Opportunities (8)
- Sun Pharma/Lerodalcibep Deal↓ (OPPORTUNITY)◆
Exclusive rights to a US FDA-approved PCSK9 inhibitor (Lerochol) for ex-US/China markets. EU approval already secured. Targeting $3.7B market growing at 38% CAGR. Could be a blockbuster for Sun's Innovative Medicines portfolio
- Lupin/Apixaban Oral Suspension↓ (OPPORTUNITY)◆
Novel liquid formulation of Eliquis® addresses an unmet need (patients with swallowing difficulties). First-to-market potential in oral liquid segment. Manufacturing in US (NJ) reduces supply chain risk
- Zydus Lifesciences/USFDA Compliance↓ (OPPORTUNITY)◆
Clean inspection (1 observation, no data integrity) at Ahmedabad SEZ II plant. Strong regulatory track record could support faster approvals for other products from this facility
- Torrent Pharma/Renewable Energy Investment↓ (OPPORTUNITY)◆
Captive hybrid (Solar+Wind) power project in Gujarat will reduce long-term energy costs and ensure regulatory compliance. 26% stake in SPV provides cost advantage vs. peers
- Cipla/Q2 FY27 Results↓ (OPPORTUNITY)◆
Board meeting on Oct 27, 2026. Watch for revenue growth from US generics and domestic formulations. Trading window closure suggests no material undisclosed events
- Sun Pharma/Postal Ballot Approval↓ (OPPORTUNITY)◆
Shareholder approval for resolution indicates strong management credibility. Could pave way for further strategic moves
- Mankind Pharma/Portfolio Rationalization↓ (OPPORTUNITY)◆
Liquidation of BSV may free up capital and management bandwidth. Could signal focus on core profitable businesses. Watch for reinvestment in high-growth areas
- Glenmark Pharma/Q2 FY27 Results↓ (OPPORTUNITY)◆
Trading window closure from Oct 1. Results expected in late Oct/early Nov. Watch for margin improvement and US business recovery
Sector Themes (5)
- Pipeline Expansion via Licensing◆
Sun Pharma's PCSK9 deal and Lupin's Apixaban approval highlight a theme of pipeline strengthening through licensing and novel formulations. Companies are moving beyond generics into innovative/specialty products
- Regulatory Compliance Focus◆
Zydus' clean USFDA inspection and Torrent's renewable energy investment show increasing focus on regulatory compliance (cGMP, captive power norms). Companies are proactively managing risks
- Portfolio Rationalization◆
Mankind Pharma's BSV liquidation suggests a trend of pruning non-core or underperforming assets. Investors should watch for similar moves across the sector
- Routine Compliance Dominates◆
6 of 11 filings are routine trading window closures. This indicates a sector in a quiet period ahead of Q2 results, with limited near-term catalysts beyond earnings
- Capital Allocation to Strategic Assets◆
Torrent's increased investment in renewable energy SPV (INR 11.88 Cr) and Sun's licensing deal (confidential terms) show capital being deployed for long-term strategic advantage rather than short-term gains
Watch List (8)
-
Monitor for further disclosures on liquidation process, asset sales, and impact on Mankind's balance sheet. Key dates: Sep 7 (shareholder resolution), Sep 28 (auditor resignation). Watch for Q2 results impact
-
Track commercial launch timeline in EU and other ex-US/China markets. Watch for revenue guidance and market share data vs. Repatha/Praluent
-
Monitor for final FDA approval and launch date. Watch for patent litigation updates and competitive landscape changes
-
Track Zydus' response to the 1 observation at SEZ II plant. Watch for any escalation (warning letter, import alert) or closure letter
-
Board meeting on Oct 27, 2026. Watch for revenue growth, margin trends, and US business performance. Trading window opens Oct 29
-
Monitor completion timeline (18-21 months) for captive power project. Watch for cost savings and regulatory benefits
-
Watch for US business recovery and margin improvement. Trading window opens after results declaration
-
Trading window closes Oct 1. Results expected in late Oct. Watch for domestic formulation growth and margin trends
Filing Analyses
(11)
28-09-2026
Torrent Pharmaceuticals has amended its agreement to increase its investment in Torrent Urja 27 Private Limited, a renewable energy SPV, from INR 7,91,93,400 to INR 11,87,90,100 for a 26% stake. The enhanced investment, made via cash consideration for 1,18,79,010 equity shares, is driven by an increase in the project capacity for a captive hybrid (Solar + Wind) power project in Gujarat. The target entity has nil turnover as of March 31, 2026, and has yet to commence business operations, with the acquisition expected to be completed in 18 to 21 months.
- · The target entity, Torrent Urja 27 Private Limited, is a special purpose vehicle and currently a wholly owned subsidiary of Torrent Green Energy Private Limited.
- · The transaction is classified as a related party transaction but is stated to be carried out at arm's length.
- · The acquisition is intended to help Torrent Pharmaceuticals comply with regulatory requirements for being a captive user under Indian electricity laws.
- · The project capacity increase necessitated the enhanced investment from INR 7,91,93,400 to INR 11,87,90,100.
- · The target entity has nil turnover as of March 31, 2026, and has not yet commenced business operations.
28-09-2026
Lupin Limited has informed the stock exchanges that its trading window will be closed from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ending September 30, 2026. This is a routine procedural closure under SEBI insider trading regulations, with no financial data or business performance disclosed.
- · Trading window closure period: October 1, 2026, until 48 hours after declaration of Q2/H1 FY27 results.
- · The date of the Board Meeting for results declaration will be announced later.
- · Filing made to both NSE (Symbol: LUPIN) and BSE (Scrip Code: 500257).
28-09-2026
Mankind Pharma Limited informed exchanges that S.R. Batliboi & Co. LLP, statutory auditors of its wholly owned subsidiary Bharat Serums and Vaccines Limited (BSV), resigned effective September 28, 2026, due to the initiation of voluntary liquidation proceedings of BSV under the Insolvency and Bankruptcy Code, 2016. The auditors confirmed no other material reason for resignation. The liquidation process was resolved by BSV shareholders on September 7, 2026, and the auditors had completed the audit for FY2026 but had not commenced the audit for FY2027.
- · BSV shareholders resolved to voluntarily liquidate the company on September 7, 2026.
- · The auditors were appointed on September 22, 2025, for a 4-year term ending at the 36th AGM.
- · The resignation is effective immediately from September 28, 2026.
- · The liquidator is prohibited from engaging any professional who served as auditor in the five years preceding liquidation commencement.
- · The auditors completed the audit for the year ended March 31, 2026, and had not started the audit for FY2027.
28-09-2026
Glenmark Pharmaceuticals has announced a closure of its trading window for designated persons from October 1, 2026, until the declaration of its unaudited financial results for Q2 FY27 (ending September 30, 2026) plus 48 hours. This routine compliance disclosure under SEBI's insider trading regulations does not contain any financial results or material business developments.
- · Trading window closure starts October 1, 2026
- · Closure ends after declaration of Q2 FY27 unaudited results plus 48 hours
- · Affects Directors, KMPs, identified employees, and their immediate relatives
- · Board meeting date for results will be announced later
28-09-2026
Zydus Lifesciences disclosed that the USFDA concluded a cGMP inspection at its SEZ II, Ahmedabad manufacturing plant on September 28, 2026, after a week-long audit. The inspection closed with one observation and no data integrity issues, and the company stated it will work expeditiously with the USFDA to address the observation. While the outcome appears relatively favorable given the absence of data integrity findings, the receipt of an observation indicates potential compliance concerns that could impact the plant's regulatory standing.
- · USFDA cGMP inspection conducted from September 21 to 28, 2026 at SEZ II, Ahmedabad plant
- · No data integrity related observations were made during the inspection
- · Disclosure made pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015
28-09-2026
Cipla Limited has informed the stock exchanges that a Board Meeting will be held on October 27, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The trading window will be closed from October 1, 2026, to October 29, 2026, in compliance with insider trading regulations.
- · Trading window closure: October 1, 2026 to October 29, 2026 (both days inclusive).
- · Board meeting date: Tuesday, October 27, 2026.
- · Financial results to be considered: unaudited standalone and consolidated results for Q2 and H1 FY27.
28-09-2026
Sun Pharmaceutical Industries Limited announced the completion of its Postal Ballot process initiated on August 25, 2026, with the resolution approved by shareholders by the requisite majority. The remote e-voting period ran from August 28 to September 26, 2026. No financial figures or performance metrics were disclosed in this filing.
- · Postal Ballot notice dated 25 August 2026
- · Remote e-voting period: 28 August 2026 to 26 September 2026
- · Resolution approved by shareholders by requisite majority
- · Scrutinizer’s Report available on company website
28-09-2026
Sun Pharma and LIB Therapeutics announced an exclusive licensing, commercialization, and manufacturing agreement for lerodalcibep (Lyrokaul), a once-monthly PCSK9 inhibitor, covering territories ex-US and China, with EU approval received on September 21, 2026. The deal grants Sun Pharma access to a US$3.7 billion PCSK9 market (ex-US/China) growing at 38% CAGR, strengthening its Innovative Medicines portfolio, though financial terms remain confidential and the drug faces competition and safety considerations.
- · EU approval received on September 21, 2026
- · Lerodalcibep is US FDA-approved under brand name Lerochol
- · Excluded China territory includes mainland China, Hong Kong, Macau, and Taiwan
- · EU label allows room temperature storage up to 25°C for six months after removal from refrigeration
- · Common side effects include injection site reactions; higher rate in patients with treatment-emergent ADA
- · No interaction studies performed; caution in severe renal/hepatic impairment
- · Not studied in pregnant women or during breastfeeding; animal data show excretion in milk
- · 33% of EU patients on stable therapy achieved risk-based goals (DA VINCI study)
- · Sun Pharma's Global Innovative Medicines portfolio accounts for about 22% of company sales
28-09-2026
Lupin Limited announced it has received tentative approval from the U.S. FDA for its New Drug Application for Apixaban Oral Suspension 1.25 mg/mL via the 505(b)(2) pathway. The product is a novel oral liquid formulation of apixaban (the active ingredient in Eliquis®), offering an alternative administration option for adult patients requiring anticoagulation therapy, especially those who have difficulty swallowing tablets. Upon final approval, the product will be manufactured at Lupin's Somerset, New Jersey facility.
- · The tentative approval was announced on September 28, 2026.
- · The product is an oral liquid formulation of apixaban, the active ingredient in Eliquis® of Bristol Myers Squibb.
- · Upon final approval, manufacturing will take place at Lupin's Somerset, New Jersey facility.
- · Lupin has a diversified portfolio spanning generics, complex generics, specialty medicines, and biosimilars.
- · The company operates 15 state-of-the-art manufacturing facilities and 6 research centers.
- · Lupin has a dedicated workforce of over 26,000 professionals.
28-09-2026
Abbott India Limited has announced the closure of its trading window for designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter ending September 30, 2026. This is a routine regulatory disclosure under SEBI's insider trading regulations and does not contain any financial data or performance metrics.
- · Trading window closure effective from October 1, 2026.
- · Trading window reopens 48 hours after declaration of Q3 FY26 (quarter ending September 30, 2026) unaudited financial results.
- · Applies to designated persons and their immediate relatives.
- · Scrip Code: 500488 on BSE Limited.
28-09-2026
Torrent Pharmaceuticals Limited has informed stock exchanges that the trading window for designated persons will be closed from October 1, 2026, until 48 hours after the submission of financial results for the quarter ending September 30, 2026. This is a routine compliance disclosure under SEBI regulations and does not contain any financial or operational data.
- · Trading window closure starts October 1, 2026.
- · Trading window reopens 48 hours after submission of Q2 FY27 (quarter ending September 30, 2026) financial results.
Get daily alerts with 11 investment signals, 7 risk alerts, 8 opportunities and full AI analysis of all 11 filings
₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: BSE Pharma Sector Regulatory Filings
September 18, 2026
BSE Pharma Sector Regulatory Filings — September 18, 2026
September 17, 2026
BSE Pharma Sector Regulatory Filings — September 17, 2026
September 16, 2026
BSE Pharma Sector Regulatory Filings — September 16, 2026
September 15, 2026
BSE Pharma Sector Regulatory Filings — September 15, 2026
🇮🇳 More from India
View all →September 21, 2026
India Upcoming Corporate Actions BSE NSE — September 21, 2026
India Upcoming Corporate Actions BSE NSE
September 21, 2026
India Pre-Market Regulatory Roundup — September 21, 2026
India Pre-Market Regulatory Roundup
September 21, 2026
India Quarterly Results BSE NSE Announcements — September 21, 2026
India Quarterly Results BSE NSE Announcements
September 21, 2026
India AGM EGM Shareholder Meeting Schedule — September 21, 2026
India AGM EGM Shareholder Meeting Schedule